

OTHER PUBLICATIONS

- Rodriguez et al., "The vaccinia virus 14-kilodalton fusion proteins forms a stable complex with the processed protein encoded by the vaccinia virus A17L gene", *J. Virology*, Jun. 1993, vol. 67, No. 6, pp. 3435-3440.
- Lai et al., "The purified 14-kilodalton envelope protein of vaccinia virus produced in *Escherichia coli* induces virus immunity in animals", *J. Virology*, Oct. 1991, vol. 65, No. 10, pp. 5631-5635.
- Rodriguez and Esteban, "Mapping and nucleotide sequence of the vaccinia virus gene that encodes a 14-kilodalton fusion protein," *J. Virology*, Nov. 1987, vol. 61, No. 11, pp. 3550-3554.
- Rodriguez et al., "Isolation and characterization of neutralizing monoclonal antibodies to vaccinia virus", *J. Virology*, Nov. 1985, vol. 56, No. 2, pp. 482-488.
- NCBI PubMed medline, Abstract for Rodriguez et al., "Isolation and characterization of neutralizing monoclonal antibodies to vaccinia virus", *J. Virology*, Nov. 1985, vol. 56, No. 2, pp. 482-488.
- Lin et al., "Vaccinia virus envelope H3L protein binds to cell surface heparan sulfate and is important for intracellular mature virion morphogenesis and virus infection in vitro and in vivo", *J. Virology*, Apr. 2000, vol. 74, No. 7, pp. 3353-3365.
- Gordon et al., "A prominent antigenic surface polypeptide involved in the biogenesis and function of the vaccinia virus envelope". *Virology* 181, pp. 671-686 (1991).
- Ichihashi et al., "Identification of a vaccinia virus penetration protein", *Virology* 202, pp. 834-843 (1994).
- Demkowicz et al., "Identification and characterization of vaccinia virus genes encoding proteins that are highly antigenic in animals and are immunodominant in vaccinated humans", *J. Virology*, Jan. 1992, vol. 66, No. 1, pp. 386-398.
- Wilson et al., "Ebola virus: the search for vaccines and treatments", *CMLS Cell., Mol. Life Sci.*, 58 (2001) pp. 1-16.
- Pushko et al., "Venezuelan Equine Encephalitis virus replicon vector: immunogenicity studies with ebola NP and GP genes in guinea pigs", *Vaccines 97, Molecular Approaches to the Control of Infectious Diseases*, Cold Spring Harbor Laboratory Press. 1997, pp. 253-258.
- Geisbert et al., "Evaluation in nonhuman primates of vaccines against Ebola virus", *Perspectives, Emerging Infectious Diseases*, vol. 8, No. 5, May 2002, pp. 503-507.
- Pushko et al., "Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus", *Vaccine* 11 (2000) pp. 1-12.
- Wilson et al., "Vaccine potential of Ebola virus VP24, VP30, VP35, and VP40 proteins", *Virology* 286, pp. 384-390 (2001).
- Wilson and Hart, "Protection from Ebola virus mediated by cytotoxic T lymphocytes specific for the viral nucleoprotein", *J. Virology*, Mar. 2001, vol. 75, No. 6, pp. 2660-2664.
- Maruyama et al., "Recombinant human monoclonal antibodies to Ebola virus", *J. Infectious Diseases*, 1999, 179 (Suppl I), pp. S235-S239.
- Jahrling et al., "Evaluation of immune globulin and recombinant interferon-alpha2b for treatment of experimental Ebola virus infections", *J. Infectious Diseases*, 1999, 170 (Suppl I), pp. S224-S234.
- Volchkov et al., "Release of viral glycoproteins during Ebola virus infection", *Virology* 245, pp. 110-119 (1998).
- GenBank, Database printout, for Sanchez et al., Ebola virus nucleoprotein, polymerase complex protein (VP35), matrix protein (VP40), glycoprotein (GP), minor nucleoprotein (VP30), and membrane-associated structural protein (VP24), Oct. 14, 1997 (7 pages).
- Hevey et al., "Antigenicity and vaccine potential of Marburg virus glycoprotein expressed by baculovirus recombinants", *Virology* 239, pp. 206-216 (1997).
- Maruyama et al., "Ebola virus can be effectively neutralized by antibody produced in natural human infection", *J. Virology*, Jul. 1999, vol. 73, No. 7, pp. 6024-6030.
- Wilson et al., "Ebola virus: the search for vaccines and treatments", *CMLS, Cell. Mol. Life Sci.* 58 (2001), pp. 1826-1841.
- Maruyama et al., "Recombinant human monoclonal antibodies to Ebola virus", *J. Infectious Diseases*, 1999, 179 (Suppl I), pp. S235-S239).
- Sanchez et al., "The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing", *PNAS, USA*, vol. 93, pp. 3602-3607, Apr. 1996.
- Jahrling et al., "Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses", *Arch Virol*, 1996 (Suppl) 11, pp. 135-140.
- Parren et al., "Pre- and postexposure prophylaxis of ebola virus infection in an animal model by passive transfer of a neutralizing human antibody", *J. Virology*, Jun. 2002, vol. 76, No. 12, pp. 6408-6412.
- Wilson et al., "Epitopes involved in antibody-mediated protection from ebola virus", *Science*, vol. 287, pp. 1664-1666, Mar. 3, 2000.
- Sanchez et al., "Detection and molecular characterization of ebola viruses causing disease in human and nonhuman primates", *J. Infectious Diseases*, 1999, vol. 179 (Suppl. I), pp. S164-S169.
- Sanchez et al., "Biochemical analysis of the secreted and virion glycoproteins of ebola virus", *J. Virology*, Aug. 1998, vol. 72, No. 8, pp. 6442-6447.
- Khaw et al., "Technetium-99m labeling of antibodies to cardiac myosin fab and to human fibrinogen", *Radiochemistry and Radiopharmaceuticals, J. Nucl. Med.*, vol. 23, No. 11, pp. 1011-1019, Nov. 1982.
- Farid et al., "Idiotypes, paratopes and molecular mimicry", pp. 1-5, and "An idiotypic approach for a vaccine against hepatitis B surface antigen", pp. 285-300, both in *Anti-Idiotypes, Receptors, and Molecular Mimicry*, Ivy Springer-Verlag, 1988.
- Kabat et al., *Sequence of proteins of immunological interest*, vol. 1, Fifth ed., pp. xiv-xix and 33 pages of sequences (1991).
- Waldmann, "Manipulation of T-cell responses with monoclonal antibodies", *Ann. Rev. Immunol.* (1989) 7:407-444.
- Kennedy et al., "Review: Protein-protein coupling reactions and the applications of protein conjugates", *Clinica Chimica Acta* 70 (1976) pp. 1-31.
- "Continuous cultures of fused cells secreting antibody of predefined specificity", *Nature*, vol. 256, pp. 495-497 (1975).
- Volchkov et al., "Processing of the ebola virus glycoprotein by the proprotein convertase furin", *PNAS USA*, vol. 95, pp. 5762-5767 (May 1998).
- Stiles et al., "Production and characterization of monoclonal antibodies against NAJA NAJA ATRA cobrotoxin", *Toxicon*, vol. 29, No. 10, pp. 1195-1204 (1991).
- Feldmann et al., "Marburg virus, a filovirus: messenger RNAs, gene order, and regulatory elements of the replication cycle", *Virus Research*, 24 (1992) pp. 1-19.
- Peters and LeDuc, "An introduction to ebola: the virus and the disease", *J. Infectious Diseases*, 1999, vol. 179 (Suppl I), pp. ix-xvi.
- Kudoyarova-Zubavichene et al., "Preparation and use of hyperimmune serum for prophylaxis and therapy of ebola virus infections", *J. Infectious Diseases*, 1999, vol. 179 (Suppl I), pp. S218-S223.
- Moe et al., "Plaque assay for ebola virus", *J. Clinical Microbiology*, Apr. 1981, vol. 13, No. 4, pp. 791-793.
- Waldmann, "Manipulation of T-cell responses with monoclonal antibodies", *Ann. Rev. Immunol.*, 1989, vol. 7, pp. 407-444.
- Mikhailov et al., "An evaluation of the possibility of ebola fever specific prophylaxis in baboons", *Voprosy Virusologii*, No. 2, pp. 82-84, 1994.
- Harlow and Lane, "Antibodies: A Laboratory Manual", Chapter 6, pp. 210-213 (Cold Spring Harbor Laboratory, New York) 1988.
- Schuurs and Van Weemen, "Review" *Enzyme-Immunoassay, Clinica Chimica Acta*, 81 (1977), pp. 1-40.
- PubMed Abstract from National Library of Medicine, Sanderson et al., "The vaccinia virus A27L protein is needed for the microtubule-dependent transport of intracellular mature virus particles", from *Virology* 1999, 264(2), at pp. 298-318.
- Gilligan et al., "Assessment of protective immunity conferred by recombinant vaccinia viruses to guinea pigs challenged with ebola virus", *Vaccines 97*, 1997, pp. 87-92.
- Xu et al., "Immunization for ebola virus infection", *Nature Medicine*, NO. 4, No. 1, Jan. 1998, pp. 37-42.
- Davis et al., "A viral vaccine vector that expresses foreign genes in lymph nodes and protects against mucosal challenge", *J. Virology*, Jun. 1996, vol. 70, No. 6, pp. 3781-3787.